Skip to main content
  • Register
  • Help
  • Contact us

C4X Discovery Holdings plc (C4XD) Ordinary Shares 1p

Sell:41.00p Buy:42.00p 0 Change: 3.75p (9.93%)
Market closed Prices as at close on 7 May 2021 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:41.00p
Buy:42.00p
Change: 3.75p (9.93%)
Market closed Prices as at close on 7 May 2021 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:41.00p
Buy:42.00p
Change: 3.75p (9.93%)
Market closed Prices as at close on 7 May 2021 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

C4X Discovery Holdings plc is a drug discovery and development company. The Company is engaged in the provision of technologies to improve the drug discovery process for small molecule therapies. Its discovery portfolio targets addiction, diabetes, inflammatory diseases and oncology, and includes small molecule versions of marketed biologics. Its products include Orexin-1, NRF-2, GPR142, GLP-1, Anti-IL-17, SGC Collaboration and Target 1. Its primary indication for its oral Orexin-1 antagonists is for the treatment of nicotine addiction as an aid to smoking cessation. It has two drug discovery programs targeting inflammatory disorders: oral Nrf-2 activators for the treatment of Chronic Obstructive Pulmonary disease (COPD) and oral/topical IL-17 inhibitors for the treatment of Psoriasis. IL-17 is implicated in multiple inflammatory and autoimmune diseases. Its suite of technologies include Taxonomy3, Conformetrix and MolPlex.

Contact details

Address:
Manchester One, 53 Portland Street
MANCHESTER
M1 3LD
United Kingdom
Telephone:
+44 (0161) 2355085
Website:
https://www.c4xdiscovery.com/

Important dates

Future events
There are no future events available.
Past events
Interim results 29 April 2021 29/04/21
AGM 19 January 2021 19/01/21
Annual report 18 December 2020 18/12/20
Final results 10 December 2020 10/12/20
General meeting 09 November 2020 09/11/20

General stock information

EPIC:
C4XD
ISIN:
GB00BQQ2RV18
Market cap:
£93.93 million
Shares in issue:
226.35 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel


Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.